Evidence Regarding Pharmacogenetics in Pain Management and Cancer

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, D Max, Figg, William D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020807/
https://www.ncbi.nlm.nih.gov/pubmed/36718020
http://dx.doi.org/10.1093/oncolo/oyac277
_version_ 1784908348126134272
author Smith, D Max
Figg, William D
author_facet Smith, D Max
Figg, William D
author_sort Smith, D Max
collection PubMed
description Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
format Online
Article
Text
id pubmed-10020807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100208072023-03-18 Evidence Regarding Pharmacogenetics in Pain Management and Cancer Smith, D Max Figg, William D Oncologist Commentaries Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics. Oxford University Press 2023-01-30 /pmc/articles/PMC10020807/ /pubmed/36718020 http://dx.doi.org/10.1093/oncolo/oyac277 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Commentaries
Smith, D Max
Figg, William D
Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title_full Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title_fullStr Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title_full_unstemmed Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title_short Evidence Regarding Pharmacogenetics in Pain Management and Cancer
title_sort evidence regarding pharmacogenetics in pain management and cancer
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020807/
https://www.ncbi.nlm.nih.gov/pubmed/36718020
http://dx.doi.org/10.1093/oncolo/oyac277
work_keys_str_mv AT smithdmax evidenceregardingpharmacogeneticsinpainmanagementandcancer
AT figgwilliamd evidenceregardingpharmacogeneticsinpainmanagementandcancer

Ejemplares similares